Taxol adjuvant therapy trial
Executive Summary
"No statistically significant difference" was shown between the control and treatment arms in the third interim analysis of a National Surgical Adjuvant Breast and Bowel Project study (B-28) "evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary nodes" presented by Aultman Hospital Cancer Center Medical Director Eleftherios Mamounas, MD, at the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Nov. 2